Cytomegalovirus (CMV)-based vectors are uniquely capable of inducing longterm effector memory T cell responses and escaping vector-specific immunity. However, fully replicative vectors are unlikely to be approved for human use given the pathogenic potential of CMV, particularly in pregnant women and immunocompromised individuals. A central goal is therefore to increase vector safety while maintaining immunogenicity and efficacy. In this project, we will define how acute and persistent replication correlates with the ability of rhesus CMV to induce a T cell response to simian immunodeficiency virus (SIV). Preliminary data suggest that severely attenuated RhCMV can still induce CMV-specific immune responses in sero-negafive animals consistent with persistent antigen production. Unlike the parental vector however, the such low-cycle vectors do not seem to be secreted from inoculated animals. Importanfiy, low-cycle vectors expressing simian immunedeficiency virus (SIV) antigens super-infect sero-positive animals and induce an SIV-specific T cell response suggesfing retention of immunogenicity. In three specific aims we will determine the extent to which vectors can be rendered replication-incompetent without sacrificing immunogenicity and the pathogenicity of such vectors in the immunocompromised.
Specific Aim 1 is to further reduce the ability of RhCMV/SIV vectors to replicate by construcfing single-cycle vectors. In addifion, we will construct vectors whose replication can be externally controlled thus allowing us to study the role of viral replicafion and spreading for the establishment and maintenance of persistent anfigen producfion and T cell stimulation.
Specific Aim 2 is to determine the pathogenicity of replicafion-deficient vectors in an animal model of congenital infecfion. A further aim is to compare their ability to induce robust SIV-specific effector memory T cell responses in sero-positive animals.
Specific Aim 3 is to generate vectors combining the lowest pathogenicity with the highest immunogenicity for efficacy studies and to confirm that corresponding human CMV vectors are attenuated in a novel animal model of latent infection. Thus, we expect that the attenuation strategy developed here will be direcfiy translatable into HCMV/HIV vectors.
The goal of this project is to increase the safety of an HIV vaccine delivered by cytomegalovirus. This will be achieved by removing essential genes from the cytomegalovirus genome thus generating a replicafion- deficient vaccine. We will test whether the resulfing vaccine is safe while retaining the advantageous immunizing characteristics of the replicating vaccine. PROJECT/PERFORIVIANCE SITE(S) (if additional space is needed, use Project/Perfonmance Site Fomnat Page) Project/Performance
|Früh, Klaus; Picker, Louis (2017) CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination. Curr Opin Immunol 47:52-56|
|McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81|
|Hansen, Scott G; Wu, Helen L; Burwitz, Benjamin J et al. (2016) Broadly targeted CD8? T cell responses restricted by major histocompatibility complex E. Science 351:714-20|
|Hansen, Scott G; Sacha, Jonah B; Hughes, Colette M et al. (2013) Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340:1237874|
|Hansen, Scott G; Piatak Jr, Michael; Ventura, Abigail B et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502:100-4|
|Masopust, David; Picker, Louis J (2012) Hidden memories: frontline memory T cells and early pathogen interception. J Immunol 188:5811-7|
|Malouli, Daniel; Nakayasu, Ernesto S; Viswanathan, Kasinath et al. (2012) Reevaluation of the coding potential and proteomic analysis of the BAC-derived rhesus cytomegalovirus strain 68-1. J Virol 86:8959-73|